combination therapy cost effective in alzheimer’s

PharmacoEconomics & Outcomes News 660 - 18 Aug 2012 Combination therapy cost effective in Alzheimer’s Combination therapy with cholinesterase inhibitors plus memantine is a cost-effective approach to the management of Alzheimer’s disease in Switzerland, report researchers from that country. They developed a Markov model using European prevalence and Swiss population data, along with figures from the published literature. Swiss sources were used to calculate direct and indirect costs. Compared with currently-funded monotherapy with either cholinesterase inhibitors or memantine, using the drug combination was estimated to cost an additional SwF1.7–1.9 million from 2012 to 2016. From a healthcare system perspective, use of combination therapy would save SwF27 655 over 5 years compared with cholinesterase inhibitor therapy alone, with an incremental cost-effectiveness ratio of SwF248 895 per QALY gained. The combination strategy was considered to be dominant over the long term. Pfeil AM, et al. Economic evaluation of the combination therapy of a Cholinesterase inhibitor and Memantine in Alzheimer’s dementia in Switzerland. 2012 International Conference on Alzheimer’s Disease : abstr. P2-361, 14 Jul 2012. Available from: URL: http://aaic.sclivelearningcenter.com/ index.aspx?PID=958 803075068 1 PharmacoEconomics & Outcomes News 18 Aug 2012 No. 660 1173-5503/10/0660-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Upload: nguyencong

Post on 18-Mar-2017

212 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

PharmacoEconomics & Outcomes News 660 - 18 Aug 2012

Combination therapy cost effectivein Alzheimer’s

Combination therapy with cholinesterase inhibitorsplus memantine is a cost-effective approach to themanagement of Alzheimer’s disease in Switzerland,report researchers from that country.

They developed a Markov model using Europeanprevalence and Swiss population data, along withfigures from the published literature. Swiss sourceswere used to calculate direct and indirect costs.

Compared with currently-funded monotherapy witheither cholinesterase inhibitors or memantine, using thedrug combination was estimated to cost an additionalSwF1.7–1.9 million from 2012 to 2016. From ahealthcare system perspective, use of combinationtherapy would save SwF27 655 over 5 years comparedwith cholinesterase inhibitor therapy alone, with anincremental cost-effectiveness ratio of SwF248 895 perQALY gained. The combination strategy was consideredto be dominant over the long term.Pfeil AM, et al. Economic evaluation of the combination therapy of aCholinesterase inhibitor and Memantine in Alzheimer’s dementia in Switzerland.2012 International Conference on Alzheimer’s Disease : abstr. P2-361, 14 Jul2012. Available from: URL: http://aaic.sclivelearningcenter.com/index.aspx?PID=958 803075068

Artemisinin-based combination therapy for treating

Combination Immunotherapy Approaches - GBCC Page.pdf · Combination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy ... • Grant funding from

Insulin Therapy for Alzheimer’s Disease

Hyperbaric oxygen therapy for Alzheimer’s dementia with ... · Hyperbaric oxygen therapy for Alzheimer’s dementia with positron emission tomography imaging: a case report. Med

Pathophysiology of Combination Therapy in AMI

Combination Therapy with a Second-Generation Androgen ......Cancer Therapy: Preclinical Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine

Early Combination Antiretroviral Therapy in Infants

Alzheimer’s Disease & Recreational Therapy FRIENDS WITH BENEFITS

Ezastatin ( The Art of Combination Therapy)

Polymyxins–Curcumin Combination Antimicrobial Therapy

Antimicrobial Photodynamic Therapy in Combination with

Combination Therapy of Chronic Hepatitis Delta